NASDAQ:ENLV Enlivex Therapeutics Q2 2024 Earnings Report $1.04 -0.05 (-4.59%) Closing price 04:00 PM EasternExtended Trading$1.04 0.00 (0.00%) As of 05:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Enlivex Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.22Beat/MissBeat by +$0.06One Year Ago EPSN/AEnlivex Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEnlivex Therapeutics Announcement DetailsQuarterQ2 2024Date8/30/2024TimeN/AConference Call DateThursday, August 29, 2024Conference Call Time6:00PM ETUpcoming EarningsEnlivex Therapeutics' Q1 2025 earnings is scheduled for Friday, August 29, 2025, with a conference call scheduled on Thursday, September 4, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim report Enlivex Therapeutics Earnings HeadlinesEnlivex Therapeutics (ENLV) Expected to Announce Earnings on FridayAugust 27 at 2:10 AM | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Earns Buy Rating from D. Boral CapitalAugust 20, 2025 | americanbankingnews.comTop Picks for Trump’s Pro-Crypto America27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your spot for FREE.August 28 at 2:00 AM | Crypto 101 Media (Ad)Enlivex stock soars after positive knee osteoarthritis trial dataAugust 18, 2025 | investing.comEnlivex Therapeutics announces topline data from Phase I/II trial of AllocetraAugust 18, 2025 | msn.comEnlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee OsteoarthritisAugust 18, 2025 | globenewswire.comSee More Enlivex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email. Email Address About Enlivex TherapeuticsEnlivex Therapeutics (NASDAQ:ENLV), together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.View Enlivex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures Upcoming Earnings Alibaba Group (8/29/2025)Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Micron Technology (9/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access